CC BY
22
Российский медико-биологический вестник
ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ Том 31, № 2, 2023 имени академика И. П. Павлова
УДК 618.19-006.6-008.93:577.122
DOI: https://doi.org/10.17816/PAVL0VJ108478
Экспрессия белка Forkhead box P3 (FOXP3) инфильтрирующих опухоль лимфоцитов при инвазивном раке молочной железы: связь с гистопатологическими параметрами и общей выживаемостью
S . Hagone, P. U . Bharat, A. GuptaH, G . Nitin
Mahatma Gandhi Institute of Medical Science, Maharashtra, India
АННОТАЦИЯ
Обоснование. Белок Forkhead box P3 (FOXP3) экспрессируется как в опухолевых клетках, так и в инфильтрирующих опухоль лимфоцитах (TILs) и, как сообщается, ассоциирован с различиями в клинических исходах . Актуальные литературные данные свидетельствуют о том, что FOXP3 позитивные (FOXP3+) Т-регуляторные клетки (Tregs) влияют на противоопухолевый иммунитет при солидных опухолях.
Цель. Определить экспрессию FOXP3+ в Tregs, связанную с различными прогностическими факторами, при карциноме молочной железы (КМЖ) в популяции Центральной Индии, а также взаимосвязь FOXP3+ Tregs c выживаемостью при инвазивной протоковой КМЖ с различными гистопатологическими проявлениями.
Материалы и методы. Это ретроспективное и проспективное обсервационное исследование, в котором FOXP3+ Tregs были подсчитаны в околоопухолевой области методом иммуногистохимии в 47 последовательных случаях КМЖ, прооперированных и подтвержденных. Пациенты находились под наблюдением в течение 48-69 месяцев на предмет прогрессирования заболевания .
Результаты. В исследуемой области преобладают (n = 30) опухоли высокой степени злокачественности независимо от стадии клинической картины . Пациенты, которые могли придерживаться своего плана лечения, оставались без неблагоприятных исходов до конца периода наблюдения, длившегося 69 месяцев (р = 0,001) . Ни один молекулярный подтип в нашем исследовании не выявил специфической склонности к высокому количеству Tregs в околопухолевой области. Никакие другие клинические или патологические параметры существенно не коррелировали с количеством FOXP3+ Tregs, в том числе общая и безрецидивная выживаемость Заключение. Исследование продемонстрировало, что люминальная КМЖ, негативная по рецепторам эпидермального фактора роста человека 2, и КМП, положительная по рецепторам эпидермального фактора роста человека 2, демонстрируют сравнительно высокое количество FOXP3+ Tregs . При этом не выявлено ассоциации со степенью опухоли, стадией TNM, важными иммунными маркерами, общей и безрецидивной выживаемостью .
Ключевые слова: FOXP3; инфильтрирующие опухоль лимфоциты; карцинома молочной железы Для цитирования:
Hagone S., Bharat P.U., Gupta A., Nitin G. Экспрессия белка Forkhead box P3 (F0XP3) инфильтрирующих опухоль лимфоцитов при инвазивном раке молочной железы: связь с гистопатологическими параметрами и общей выживаемостью // Российский медико-биологический вестник имени академика И. П. Павлова. 2023. Т. 31, № 2. С. 265-272. D0I: https://doi.org/10.17816/PAVL0VJ108478
Рукопись получена: 02 . 06 . 2022 Рукопись одобрена: 16 . 09 . 2022 Опубликована: 30 . 06 . 2023
Э К о . В Е К Т О Р Лицензия СС BY-NC-ND 4.0
© Коллектив авторов, 2023
ORIGINAL STUDY ARTICLES 266 -
DOI: https://doi.org/10.17816/PAVL0VJ108478
Expression of FOXP3 of Tumor-Infiltrating Lymphocytes in Invasive Breast Cancer: Its Relationship to Histopathological Parameters and Overall Survival
Swati Hagone, Patil U . Bharat, Anupama GuptaH, Gangane Nitin
Mahatma Gandhi Institute of Medical Science, Maharashtra, India
ABSTRACT
BACKGROUND: Forkhead box P3 protein (FOXP3) is expressed in both tumor cells and tumor-infiltrating lymphocytes (TILs) and is reported to be associated with differences in clinical outcomes . Recent literature shows that FOXP3 positive (FOXP3+) T regulator cells (Tregs) influence anti-tumor immunity in solid tumors .
AIM: To explore FOXP3+ Tregs expression related to various prognostic factors in breast carcinoma (BC) in the central Indian population . Our study is also helpful in correlating the role of FOXP3+ Tregs in the survival of invasive ductal BC with different histopathological presentations
MATERIALS AND METHODS: This is a retrospective and prospective observational study in which FOXP3+ Tregs was counted in the peritumoral area by immunohistochemistry in 47 consecutive cases of BC operated on and diagnosed already . The patients were followed for 48 to 69 months for disease progression .
RESULTS: High-grade tumors are prevalent (n = 30) in the study area irrespective of the stage of clinical presentation . Patients who could adhere to their treatment plan remained free of adverse outcomes until the end of our follow-up period of 69 months (p = 0 . 001) . No molecular subtype in our study showed specific predilection towards a high Tregs count in the peri-tumoral area . No other clinical or pathological parameters significantly correlated with FOXP3 +Treg count, including overall survival and disease-free survival .
CONCLUSION: The study shows that luminal human epidermal growth factor receptor 2 negativ and human epidermal growth factor receptor 2 enriched BC show comparatively high FOXP3+ Tregs count . There is no relation with tumor grade, TNM stage, important immune markers, or overall survival and disease-free survival .
Keywords: FOXP3; tumor-infiltrating lymphocytes; carcinoma breast For citation:
Hagone S, Bharat PU, Gupta A, Nitin G. Expression of F0XP3 of Tumor-Infiltrating Lymphocytes in Invasive Breast Cancer: Its Relationship to Histopathological Parameters and Overall Survival. I. P. Pavlov Russian Medical Biological Herald. 2023;31 (2):265—272. DOI: https://doi.org/10.17816/PAVL0VJ108478
Received: 02 . 06 . 2022 Accepted: 16 . 09 . 2022 Published: 30 . 06 . 2023
The article can be use under the CC BY-NC-ND 4.0 license
© Authors, 2023
Российский медико-биологический вестник имени академика И. П. Павлова
LIST OF ABBREVIATIONS
BC — breast carcinoma
DFS — disease-free survival
ER — estrogen-receptor
FOXP3 — forkhead box P3 protein
FOXP3+ — forkhead box P3 protein positive
HEBC — human epidermal growth factor receptor 2 enriched breast
carcinoma
HER2 — human epidermal growth factor receptor 2 HPFs — high-power fields HR — hormone receptor IHC — immunohistochemistry
IL — interleukin Lum — luminal
MGIMS — Mahatma Gandhi Institute of Medical Sciences
MRM — modified radical mastectomy
NGS — Nottingham grading system
OS — overall survival
PR — progesterone-receptor
TILs — tumor-infiltrating lymphocytes
TNBC — triple-negative breast cancer
Tregs — regulatory T cells
BACKGROUND
Breast carcinoma (BC) is the most prevalent cancer in women worldwide, with approximately 2,261,419 new cases diagnosed in females in 2020, accounting for about 24. 53% of all cancer cases worldwide and 6 . 91% of all cancer deaths [1] . In 2020, there will be 19 . 3 million cancer cases and 10 million cancer deaths worldwide Cancer incidence among Indian women is expected to reach 712,758 by 2020 (104 per 100,000) [2] . The origin of BC is unclear. However, age, genetics, genes, radiation exposure, obesity, delayed pregnancy, and alcohol are all established risk factors for this disease [3] . BC metastasis is a multi-step biological process that various genes and substances can regulate [4] As a result, in-depth research of the molecular and signal transduction pathways that play significant roles in BC metastasis is critical for understanding the mechanism of BC metastasis, both theoretically and clinically
BC is a complex disease whose development involves various factors Factors that can affect its risk include heredity and genetics and the factors affecting endogenous hormone production, like a lifestyle change, reproductive factors, ingestion of exogenous hormones, anthropometric features, mammography showing increasing breast density, and benign breast diseases [5] The number of positive axillary nodes, tumor size, tumor grade (histologic or nuclear), lymphatic and vascular invasion, and estrogen-receptor (ER) and progesterone-receptor (PR) positivity are all traditional prognostic markers . They predict the likelihood of recurrence or mortality from BC .
The grading of BC is determined using several scoring methods . The Nottingham Histological Grading System is being used, along with immunohistochemistry Tumors were only classified according to their clinical stage until the late 1950s, which ignored the accepted range of biological behavior of BCs . According to H . J . Bloom and W . W . Richardson, clinical staging 'fails to signal the likelihood of occult lymphatic and blood-borne metastases being present in what appears to be an early illness, nor the speed with which such metastases may grow'. This inspired them to design a method of histologic grading, which was updated in 1991 by C . W . Elston and I . O . Ellis . They used semiquantitative criteria
to improve objectivity and reproducibility [6] . The Elston-Ellis modification of the Bloom and Richardson grading classification (Nottingham grading system, NGS) is now widely used to guide the management of invasive BC worldwide [7] .
The transcription factor forkhead box P3 (FOXP3), which belongs to the forkhead/pterygoid family, was initially thought to be a molecular marker for regulatory T cells (Tregs) [8] . Many studies have recently revealed that FOXP3 is also a tumor suppressor gene in BC [9] . FOXP3 expression was initially thought to be limited to hematopoietic tissues only From 2007 onwards, an increase in the FOXP3 gene has been noted not in Tregs in the tumor but also in epithelial cells, acting as tumor epithelial suppressor gene The precise mechanism by which FOXP3+ tumor-infiltrating lymphocytes (TILs)/Tregs suppress immune cell function remains unclear. However, this is thought to be through a combination of contact with each other and cytokine production, with a role for interleukin (IL) 10 and transforming growth factor-3 [10] . It leads to T cell function down-regulation and prevents autoimmune disease in normal individuals [11] . Wild-type FOXP3 in normal tissue cells represses human epidermal growth factor receptor 2 (HER2) and c-myc oncogenes in mammary and prostate, respectively. FOXP3 overexpression in the human carcinoma cell line also suppresses tumor growth However, mutated FOXP3 helps in Tregs proliferation and escape of tumor cells from immune surveillance . FOXP3 protein is expressed in both tumor cells (nuclear or cytoplasmic) and TILs and is reported to be associated with differences in clinical outcomes [12] . The expression of FOXP3 in tumor cells suggests the possibility that tumor-infiltrating Tregs influence antitumor immunity and modulate T-cell function through FOXP3, raising hopes for a potential prognostic marker [11] . FOXP3+ regulatory T cells showed poor prognosis in hormone receptor (HR) positive BC However, it showed of favorable prognosis in HR-/HER2+ tumors [13] . Few studies demonstrated that CD3+, CD8+, and FOXP3+ lymphocyte densities did not add any new prognostic information to stromal TILs assessed on hematoxylin and eosin in early intermediate/high-risk BC treated with adjuvant chemotherapy [14] . Our study may fill the gap and explain the potential prognostic values of FOXP3 in BC .
This is one of the rare limited studies done on the role of FOXP3+ Tregs in our country's prognosis of BC . This study aimed to determine FOXP3+ Tregs expression related to various prognostic factors in BC in the central Indian population Our study is also helpful in correlating the role of FOXP3+ Tregs in the survival of invasive ductal carcinoma of the breast with different histopathological presentations .
MATERIALS AND METHODS
Study designs and patient selection criteria. The study was carried out at The Mahatma Gandhi Institute of Medical Sciences (MGIMS), a medical school in Sevagram in Central India . It is attached to Kasturba Hospital, a nearly 1000 bedded tertiary care rural hospital . The Histopathology section of the Department of Pathology receives approximately 6,500 specimens each year The present prospective observational study was conducted from May 2018 to August 2020 in the Histopathology section of the Department of Pathology. Forty-seven diagnosed and operated women with invasive duct carcinoma with reported ER, PR, and HER2 neu status with complete demographic records such as age, sex, diagnosis, stage, treatment, and medical records such as type and stage of cancer were included They were diagnosed two to four years back from the initiating point of the study. Patients who refused to give consent or patients lost to follow up after initial diagnosis, cases with trucut biopsy and or wedge biopsy have been performed, male patients with BC and history of recurrence and neoadjuvant therapy cases were excluded The tissue was obtained during modified radical mastectomy (MRM) and lumpectomy specimens .
Ethical considerations. This study was approved by the institutional ethics committee of MGIMS Sevagram (MGIMS/ IEC/Path/89/2018; 15 November 2018) . Informed consent was also be taken from every patient in their language regarding their willingness to participate in the study
Histopathology and Immunohistochemistry (IHC) . The selected formalin-fixed paraffin-embedded tissue block was retrieved from archives for each case Sections of 3-5 microns in thickness were obtained and stained with hematoxylin and eosin After case selection, an immunohistochemical stain for FOXP3 was performed on these sections For IHC, hematoxylin and eosin-stained slides will be screened to obtain the best section and rescreened to find the best section for FOXP3 stain 0 1ml concentrate anti-human F0XP3/NB600-246 rabbit polyclonal antibody (Novus biologicals) with preservative 0 .1% sodium azide and isotype-IgG was used, and dilution made in 1:100 with antibody diluent . F0XP3 IHC was carried out on a 3-5 ^m thick formalin-fixed, paraffin-embedded section mounted on positively charged glass slides . The criteria of S . Lee, et al . [15] were used to count F0XP3+ Tregs expression (The cut off values was 15 F0XP3+ TILs/10 high-power fields (HPFs) and for low was < 15 F0XP3+ TILs/10 HPFs and for high was > 15 F0XP3+ TILs/10 HPFs) . The F0XP3+ Tregs
were counted by a consultant pathologist who was blinded to the clinico-histological profile of the cases . Under a light microscope at 400 x magnification, ten representative fields at tumor bed and stroma were chosen . The count of the positive lymphocytes on each slide was reported as a mean value of the representative ten fields F0XP3+ Tregs were calculated only in the peritumoral region . Patient's outdoor and indoor visits to the hospital after primary management were recorded using departmental records, the hospital information system, and our population-based cancer registry, and follow-up data were collected for the disease course for 48 to 69 months .
Statistical analysis. Statistical analysis was done using descriptive and inferential statistics using the jl test and Kaplan Meire Survival Analysis . The software used in the study were SPSS 24 . 0 version and GraphPad Prism 7 . 0 version P < 0 05 is considered a level of significance
RESULTS
In our study, the peri-menopausal age group (40-59 years) is the most common age group accounting for 66 percent of our cases (n = 31), with a mean age of 49 years . We classified our study cases into four molecular subgroups based on the expression of three immune markers in the tumor cells — ER, PR, and HER2/neu . Since the Ki-67 immune marker expression was not available for the study, we could not categorize our cases into other molecular classes
Adverse outcomes were present in all 100% of cases where patients could not comply with their treatment plan for various personal and socio-economic reasons 76 33% of patients who could adhere to their treatment plan remained free of adverse outcomes until a follow-up period of 69 months (p = 0 . 001, Table 1). Treatment plan: I — Surgery + Adjuvant chemotherapy; II — Surgery + Adjuvant chemotherapy + Radiotherapy; III — Neoadjuvant chemotherapy + Surgery + Radiotherapy
The findings in our study indicate that high-grade tumors are prevalent (63 78%) in the study area irrespective of the stage of clinical presentation Most distant metastases were found in the liver, with 57 00% of distant metastasis and 44 41% of all adverse outcomes . Since luminal (Lum) HER2- and HEBC constitute maximum cases of both low and high count of F0XP3+ This finding is statistically insignificant and suggests no molecular subtype in our study with specific predilection towards high Tregs count in the peri-tumoral area (Table 2). With F0XP3+ Tregs count groups, no definite relationship is appreciated between histological grading and TNM staging
HEBC (36 00%) and Lum HER2- (36 0%) were predominant molecular subtypes with high F0XP3+ Tregs count but a statistically insignificant p-value of 0 . 74 . Also, there was no significant relationship between F0XP3+ Tregs count and individual ER, PR, and HER2 status as almost equal positive and negative study cases shows low and high count (p = 0 86, 0 86, and 0 89, respectively, Table 3) During
Российский медико-биологический вестник
ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ Том 31, № 2, 2023 имени академика И. П. Павлова
Table 1. Adverse outcomes in the context of compliance with a treatment plan
Adverse Outcome Completion of Treatment (%) Total
Completed Not completed
Absent 29 (76.34) 0 29 (61.70)
Present 9 (23.72) 9 (100) 18 (38.30)
Total 38 (80.85) 9 (19.15) 47 (100)
X2 Test 19.01, p = 0.001
Note: Adverse Outcome = Patients who had a recurrence or distant metastases or died during the follow-up Table 2. Correlation of FOXP3 with histological parameters and molecular subtypes
FOXP3+ Tregs Low, n (%) High, n (%) Total, n (%) X2 Test
Histological Grading Grade 1 0 1 (4.00) 1 (2.13) 1.06, p = 0.58
Grade 2 7 (31.82) 9 (36.00) 16 (34.04)
Grade 3 15 (68.18) 15 (60.00) 30 (63.83
Total 22 (46.81) 25 (53.18) 47 (100.00)
TNM Staging Stage I 0 3 (12.00) 3 (6.38) 3.86, p = 0.27
Stage II 9 (40.91) 8 (32.00) 17 (36.17)
Stage III 8 (36.36) 6 (24.00) 14 (29.79)
Stage IV 5 (22.73) 8 (32.00) 13 (27.66)
Total 22 (46.81) 25 (53.18) 47 (100.00)
Molecular Subtype Lum HER2+ 3 (13.64) 3 (12.00) 6 (12.77) 0.11, p=0.74
Lum HER2- 7 (31.82) 9 (36.00) 16 (34.04)
TNBC 4 (18.18) 4 (16.00) 8 (17.02)
HEBC 8 (36.36) 9 (36.00) 17 (36.17)
Notes: HEBC — human epidermal growth factor receptor 2 enriched breast carcinoma, Lum — luminal, TNBC — triple-negative breast cancer Table 3. Correlation of FOXP3+ Tregs count with ER/PR/Her2 neu status
FOXP3+ Tregs Total, n (%) X2 Test
Low, n (%) High, n (%)
ER Status
Negative 12 (48.00)%) 13 (52.00)%) 25 (53.19%) 0.03
Positive 10 (45.45%) 12 (54.55%) 22 (46.81%) p = 0.86
PR Status
Negative 12 (48.00)%) 13 (52.00)%) 25 (53.19%) 0.03
Positive 10 (45.45%) 12 (54.55%) 22 (46.81%) p = 0.86
HER2 New
Negative 11 (45.83%) 13 (54.17%) 24 (51.06%) 0.01
Positive 11 (47.83%) 12 (52.17%) 23 (48.97%) p = 0.89
Notes: ER — estrogen-receptor, FOXP3 — forkhead box P3, HER2 — human epidermal growth factor receptor 2, PR — progesterone-receptor, Tregs — regulatory T cells
the study period, 12 patients died, and 35 patients survived, all of which responded well to treatment, irrespective of whether they had a low or high FOXP3+ Tregs . The data also indicates that out of 12 death cases, 66 . 68% belong to the low FOXP3+ Treg group and 33 . 32% to the high FOXP3+ Treg group, suggesting that high FOXP3 expression is associated with a better prognosis . Mean overall survival (OS) with
high FOXP3+ Treg was 1427 . 60 ± 409 . 52 days, while with low FOXP3+ Treg was 1373 . 31 ± 361. 09 days, and it is statistically insignificant Similar findings were found with disease-free survival (DFS) . Mean DFS with high FOXP3+ Treg was 1176 . 80 ± 516 .16 days while low FOXP3+ Treg was 1151. 36 ± 487 . 82 days and are also statistically not significant (Table 4, Figure 1)
Table 4. Survival analysis of study cases with the context of F0XP3+ Tregs counts
FOXP3+ Tregs Mean DFS, days Mean OS, days Total cases, n Alive cases, n Censored
Death, n (%)
Low 1151.36 ± 487.82 1373.31 ± 361.09 22 14 8 (36.44)
High 1176.80 ± 516.16 1427.60 ± 409.52 25 21 4 (16.00)
Overall 1164.89 ± 497.80 1402.19 ± 384.41 47 35 12 (25.5.2)
Log rank test: OS — 0.47, p = 0.63 and DFS — 0.06, p = 0.86)
Notes: DFS — disease-free survival, FOXP3 — forkhead box P3, OS — overall survival
Survival Functions
Survival Functions
^J—11.00 - ^2.00 —H 1.00-ctnii -i- Ï.OO-canSi
V>
E
I
I
F0^3 Expression
-riUw
~ Lcrw -cerwured
500.00 1000,00 1500.00
Overall Survival
500 00 1000.00 1500 00
Disease free survival
Fig. 1. 0verall and disease-free survival .
DISCUSSION
F0XP3 protein is expressed in both breast tumor cells (nuclear or cytoplasmic) and TILs and is reported to be associated with differences in clinical outcomes [12] . In the present study, we evaluated the role of F0XP3+ Tregs present in the tumor area in context to the disease presentation and progression We did not find any significant association of F0X P3+ Tregs with any of these aspects of BC . The available literature is also highly divided on the role of F0XP3+ Tregs in carcinoma BC Some previous studies supported our findings, while few other data sets could not be correlated
In the present study with a small sample size (n = 47), approximately half cases (n = 25) showed high, and in the rest of the 22 patients, a low F0XP3+ Tregs count was seen . 0f these half cases (53 .19%), HEBC and Lum HER2 are predominant molecular subtypes with high F0XP3+ Tregs count . But these findings are statistically insignificant (p = 0 .74), and these findings are supported by E Papaioannou, et al [16] . They determined that F0XP3+ (Tregs) and CD8+ TILs show a high level in early-stage triple-negative breast cancer (TNBC) and the HER2+ BCs and decrease with disease progression to the advanced stages Similar to the study of M . Mohamed, et al . [17], we also could not find any correlation of F0XP3+ Tregs count with the three essential IHC markers (ER, PR, HER2) expression
We found that F0XP3+ Tregs count is not significantly associated with any histological grade or TNM stage of BC in our 47 study cases S Lee, et al also found the same in their 86 cases [15] . However, few other studies did find a significant positive correlation between high F0XP3+ TILs with a higher grade of BC [12] . Regarding mean 0S and DFS, again, we were unable to find any significant relationship at all with F0XP3+ Tregs (p = 0 . 47).
0ur findings showed partial correlation with G Peng, et al studies reported that F0XP3 expression in tumor stroma was not significantly associated with 0S [18] . However, when the entire tumor was taken into account, patients with low F0XP3 expression had a higher 0S than those with high F0XP3 expression Studies show better 0S with high F0XP3+ Tregs count but only with TNBC and HEBC [15, 19] . 0ther subtypes with high F0XP3+ Tregs are associated with worse 0S [12] . 0nly one study [20] found that the overall 5-year DFS rate was 85 . 7% in the high F0XP3 Tregs group versus 98 . 5% in the low F0XP3 Tregs group (p = 0 . 042). This shows a lack of consensus between various studies on the relation of Tregs with DFS and 0S .
Findings of the present study regarding the grade, stage, or 0S/DFS in BC cases may be explained because most of our patients presented themselves in advanced stage (stage III + IV), possibly due to socio-economic constraints .
Российский медико-биологический вестник имени академика И. П. Павлова
So, we couldn't have enough cases in the early stages of the disease to analyze these parameters satisfactorily. But the insignificance may also be either due to the counter-effect of FOXP3 expression in carcinoma cells or the effect of the TILs (CD4, CD8, and CD25), which we didn't study or due to the zonal difference in the presence of FOXP3+ Tregs as various studies counted Tregs in different tumor zones . The different cut-off values for FOXP3+ Treg used in other studies may also contribute to this difference . Less likely, the discrepancy in various studies may be due to actual differences in the genetic constitution of the study population
CONCLUSION
The study shows that luminal HER2-negative breast cancer and human epidermal growth factor receptor 2 enriched breast carcinoma show comparatively high regulatory T cells fork head box P3 count There is no relation with tumor grade, TNM stage, important immune markers, or overall survival/ disease-free survival More studies with large sample size and standardized methodology are needed to confirm our findings . We recommend standardization of methods for future studies in this domain to be compared more reliably and robustly
ADDITIONALLY
Funding. Financially aided by the Research Grant Committee of the institute Mahatma Gandhi Institute of Medical Science. Conflict of interests. The authors declare no conflicts of interests. Acknowledgment. This project was financially aided by the Research Grant Committee of the institute Mahatma Gandhi Institute of Medical Science. Contribution of the authors: S. Hagone — data collection, statistical analysis, and interpretation, text writing; P. U. Bharat — statistical analysis, and interpretation, text writing; A. Gupta—study concept and design, data collection, statistical analysis, and interpretation, text writing, editing; G. M. Nitin — text writing, editing. The authors confirm the correspondence of their authorship to the ICMJE International Criteria. All authors made a substantial contribution to the conception of the work, acquisition, analysis, interpretation of data for the work, drafting and revising the work, final approval of the version to be published and agree to be accountable for all aspects of the work.
Финансирование. При финансовой поддержке Комитета по исследовательским грантам Mahatma Gandhi Institute of Medical Science. Конфликт интересов. Авторы заявляют об отсутствии конфликта интересов. Благодарность. Этому проекту оказал финансовую поддержку Комитет по исследовательским грантам Mahatma Gandhi Institute of Medical Science. Вклад авторов: Hagone S. — сбор данных, статистический анализ и интерпретация, написание текста; Bharat P. U. — статистический анализ и интерпретация, написание текста; Gupta A. — концепция и дизайн исследования, сбор данных, статистический анализ и интерпретация, написание текста, редактирование; Nitin G. M. — написание текста, редактирование. Авторы подтверждают соответствие своего авторства международным критериям ICMJE (все авторы внесли существенный вклад в разработку концепции и подготовку статьи, прочли и одобрили финальную версию перед публикацией).
СПИСОК ИСТОЧНИКОВ
1. Sung H., Ferlay J., Siegel R.L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA: a Cancer Journal for Clinicians. 2021. Vol. 71, No. 3. P. 209-249. doi: 10.3322/caac.21660
2. Cancer Statistics — India Against Cancer. Доступно по: http://cancerindia.org.in/cancer-statistics/. Ссылка активна на 02.06.2022.
3. Breast cancer treatment | breast cancer Hospital Delhi NCR, India | RGCIRC. Доступно по: https://www.rgcirc.org/specialties/department_ surgical-oncology/breast-oncology-services/. Ссылка активна на 02.06.2022.
4. Chen Q., Lei J.H., Bao J., et al. BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis // Advanced Science. 2020. Vol. 7, No. 6. P. 1903616. doi: 10.1002/advs.201903616
5. Pashayan N., Antoniou A.C., Ivanus U., et al. Personalized early detection and prevention of breast cancer: ENVISION consensus statement // Nature Reviews. Clinical Oncology. 2020. Vol. 17, No. 11. P. 687-705. doi: 10.1038/s41571-020-0388-9
6. Van Dooijeweert C., van Diest P.J., Ellis I.O. Grading of invasive breast carcinoma: the way forward // Virchows Archiv. 2022. Vol. 480, No. 1. P. 33-43. doi: 10.1007/s00428-021-03141-2
7. Curigliano G., Burstein H.J., Winer E.P., et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 // Annals of Oncology. 2017. Vol. 28, No. 8. P. 1700-1712. doi: 10.1093/annonc/mdx308
8. Qiu R., Zhou L., Ma Y., et al. Regulatory T Cell Plasticity and Stability and Autoimmune Diseases // Clinical Reviews in Allergy & Immunology. 2020. Vol. 58, No. 1. P. 52-70. doi: 10.1007/s12016-018-8721-0
9. Kalaw E., Lim M., Kutasovic J.R., et al. Metaplastic Breast Cancers Frequently Express Immune Checkpoint Markers FOXP3 and PD-L1 // British Journal of Cancer. 2020. Vol. 123, No. 11. P. 1665-1672. doi: 10.1038/s41416-020-01065-3
10. Uva V., Sfondrini L., Triulzi T. FOXP3 expression in tumor cells and its role in cancer progression // Atlas of Genetics and Cytogenetics in Oncology and Haematology. 2015. Vol. 19, No. 3. P. 234-239.
11. Hong H., Gu Y., Zhang H., et al. Depletion of CD4+CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model // Clinical and Experimental Immunology. 2010. Vol. 159, No. 1. P. 93-99. doi: 10.1111/j.1365-2249.2009.04018.x
12. Takenaka M., Seki N., Toh U., et al. FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis // Molecular and Clinical Oncology. 2013. Vol. 1, No. 4. P. 625-632. doi: 10.3892/mco.2013.107
13. Liu S., Foulkes W.D., Leung S., et al. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration // Breast Cancer Research. 2014. Vol. 16, No. 5. P. 432. doi: 10.1186/s13058-014-0432-8
14. Koletsa T., Kotoula V., Koliou G.-A., et al. Prognostic Impact of Stromal and Intratumoral CD3, CD8 and FOXP3 in Adjuvantly Treated Breast Cancer: do They Add Information Over Stromal Tumor-Infiltrating Lymphocyte Density? // Cancer Immunology, Immunotherapy. 2020. Vol. 69, No. 8. P. 1549-1564. doi: 10.1007/s00262-020-02557-0
15. Lee S., Cho E.Y., Park Y.H., et al. Prognostic impact of FOXP3 expression in triple-negative breast cancer // Acta Oncologica. 2013. Vol. 52, No. 1. P. 73-81. doi: 10.3109/0284186X.2012.731520
16. Papaioannou E., Sakellakis M., Melachrinou M., et al. A Standardized Evaluation Method for FOXP3+ Tregs and CD8+ T-cells in Breast Carcinoma: Association with Breast Carcinoma Subtypes, Stage and Prognosis // Anticancer Research. 2019. Vol. 39, No. 3. P. 1217-1232. doi: 10.21873/anticanres.13232
17. Mohamed M.G., Sarwath H., Alqahtani S., et al. Foxp3 expression in breast cancer patient from Qatar: survival analysis // Journal for ImmunoTherapy of Cancer. 2015. Vol. 3, Suppl. 1. P. O2. doi: 10.1 186/2051-1426-3-S1-O2
18. Peng G.-L., Li L., Guo Y.-W., et ai. CD8+ cytotoxic and FoxP3+ regulatory T lymphocytes serve as prognostic factors in breast cancer // American Journal of Transiationai Research. 2019. Voi. 11, No. 8. P. 5039-5053.
19. Asano Y., Kashiwagi S., Goto W., et ai. Tumour-infiitrating CD8 to FOXP3 iymphocyte ratio in predicting treatment responses to neoadjuvant
chemotherapy of aggressive breast cancer // The British Journal of Surgery. 2016. Vol. 103, No. 107. P. 845-854. doi: 10.1002/bjs.10127 20. Kim S., Lee A., Lim W., et al. Zonal Difference and Prognostic Significance of Foxp3 Regulatory T Cell Infiltration in Breast Cancer // Journal of Breast Cancer. 2014. Vol. 17, No. 1. P. 8-17. doi: 10.4048/jbc.2014.17.1.8
REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. doi: 10.3322/caac.21660
2. Cancer Statistics — India Against Cancer [Internet]. Available at: http://cancerindia.org.in/cancer-statistics/. Accessed: 2022 June 02.
3. Breast cancer treatment | breast cancer Hospital Delhi NCR, India | RGCIRC. Available at: https://www.rgcirc.org/specialties/department_surgical-oncology/breast-oncology-services/. Accessed: 2022 June 02.
4. Chen Q, Lei JH, Bao J, et al. BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis. Adv Sci. 2020;7(6):1903616. doi: 10.1002/advs.201903616
5. Pashayan N, Antoniou AC, Ivanus U, et al. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat Rev Clin Oncol. 2020;17(1 1):687-705. doi: 10.1038/s41571-020-0388-9
6. Van Dooijeweert C, van Diest PJ, Ellis IO. Grading of invasive breast carcinoma: the way forward. Virchows Arch. 2022;480(1 ):33—43. doi: 10.1007/s00428-021-03141-2
7. Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International
Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8):1700-12. doi: 10.1093/annonc/mdx308
8. Qiu R, Zhou L, Ma Y, et al. Regulatory T Cell Plasticity and Stability and Autoimmune Diseases. Clin Rev Allergy Immunol. 2020;58(1):52-70. doi: 10.1007/s12016-018-8721-0
9. Kalaw E, Lim M, Kutasovic JR, et al. Metaplastic Breast Cancers Frequently Express Immune Checkpoint Markers FOXP3 and PD-L1. Br J Cancer. 2020;123(1 1):1665-72. doi: 10.1038/s41416-020-01065-3
10. Uva V, Sfondrini L, Triulzi T. FOXP3 expression in tumor cells and its role in cancer progression. Atlas Genet Cytogenet Oncol Haematol. 2015;19(3):234-9.
11. Hong H, Gu Y, Zhang H, et al. Depletion of CD4 +CD25 + regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model. Clin Exp Immunol. 2010;159(1):93-9. doi: 10.1111/j.1365-2249.2009.04018.x
12. Takenaka M, Seki N, Toh U, et ai. FOXP3 expression in tumor ceiis and tumor-infiitrating iymphocytes is associated with breast cancer prognosis. Mol Clin Oncol. 2013;1(4):625-32. doi: 10.3892/mco.2013.107
13. Liu S, Fouikes WD, Leung S, et ai. Prognostic significance of FOXP3+ tumor-infiitrating iymphocytes in breast cancer depends on estrogen receptor and human epidermai growth factor receptor-2 expression status and concurrent cytotoxic T-ceii infiitration. Breast Cancer Res. 2014;16(5):432. doi: 10.1186/s13058-014-0432-8
14. Koietsa T, Kotouia V, Koiiou G-A, et ai. Prognostic Impact of Stromai and Intratumorai CD3, CD8 and FOXP3 in Adjuvantiy Treated Breast Cancer: do They Add Information Over Stromai Tumor-Infiitrating Lymphocyte Density? Cancer Immunol Immunother. 2020;69(8):1549-64. doi: 10.1007/s00262-020-02557-0
15. Lee S, Cho EY, Park YH, et ai. Prognostic impact of FOXP3 expression in tripie-negative breast cancer. Acta Oncoi. 2013;52(1 ):73-81 .doi: 10.3109/0284186X.2012.731520
16. Papaioannou E, Sakeiiakis M, Meiachrinou M, et ai. A standardized evaiuation method for FOXP3+ Tregs and CD8+ T-ceiis in Breast Carcinoma: Association with breast carcinoma subtypes, stage and prognosis. Anticancer Res. 2019;39(3):1217-32. doi: 10.21873/anticanres.13232
17. Mohamed MG, Sarwath H, Aiqahtani S, et ai. Foxp3 expression in breast cancer patient from Qatar : survivai anaiysis. J Immunother Cancer. 2015;3(Suppi 1):O2. doi: 1D.1186/2D51-1426-3-S1-O2
18. Peng G-L, Li L, Guo Y-W, et ai. CD8+ cytotoxic and FoxP3+ reguiatory T iymphocytes serve as prognostic factors in breast cancer. Am J Transl Res. 2019;1 1(8):5039-53.
19. Asano Y, Kashiwagi S, Goto W, et ai. Tumour-infiitrating CD8 to FOXP3 iymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer. Br J Surg. 2016;103(7):845-54. doi: 10.1002/bjs.10127
20. Kim S, Lee A, Lim W, et ai. Zonai Difference and Prognostic Significance of Foxp3 Reguiatory T Ceii Infiitration in Breast Cancer. J Breast Cancer. 2014;17(1):8-17. doi: 10.4048/jbc.2014.17.1.8
ОБ АВТОРАХ
Hagone Swati, MD;
ORCID: https://orcid.org/0000-0002-4674-3470; e-mail: drswatihagone@gmail.com
Bharat Patil Umakant, MD, Associate Professor; ORCID: https://orcid.org/0000-0002-3364-4967; e-mail: bharatpatil@mgims.ac.in
*Gupta Anupama, MD, Professor;
ORCID: https://orcid.org/0000-0001-5598-0331;
e-mail: anupamagupta@mgims.ac.in
Nitin Gangane, MD, Professor;
ORCID: https://orcid.org/0000-0003-0190-4215;
e-mail: nitingangane@gmail.com
* Автор, ответственный за переписку / Corresponding author
AUTHOR'S INFO
Swati Hagone, MD;
ORCID: https://orcid.org/0000-0002-4674-3470; e-mail: drswatihagone@gmail.com
Patil U. Bharat, MD, Associate Professor; ORCID: https://orcid.org/0000-0002-3364-4967; e-mail: bharatpatil@mgims.ac.in
*Anupama Gupta, MD, Professor;
ORCID: https://orcid.org/0000-0001-5598-0331;
e-mail: anupamagupta@mgims.ac.in
Gangane Nitin, MD, Professor;
ORCID: https://orcid.org/0000-0003-0190-4215;
e-mail: nitingangane@gmail.com
